Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 2/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | LIPE | Q05469 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | RORC | P51449 | 1/20 | 0.41 |
| ▸ | GFER | P55789 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11985253 | 0.89 | MAPT (0.42) | MEN1KMT2APOLBCYP2C19MAPT | |
| SCHEMBL11980688 | 0.84 | POLB (0.44) | MEN1KMT2APOLBCYP2C19CYP1A2 | |
| SCHEMBL11980687 | 0.83 | ALDH1A1 (0.50) | KMT2APOLBCYP2C19CYP1A2MAPT | |
| SCHEMBL11980684 | 0.81 | ALDH1A1 (0.43) | MEN1KMT2APOLBCYP2C19MAPT | |
| SCHEMBL11980685 | 0.79 | ABHD6 (0.51) | MEN1KMT2APOLBCYP2C19CYP1A2 | |
| SCHEMBL11980694 | 0.77 | ALDH1A1 (0.67) | MAPTALDH1A1L3MBTL1 | |
| SCHEMBL11980680 | 0.75 | ALDH1A1 (0.53) | MEN1KMT2APOLBCYP2C19MAPT | |
| SCHEMBL19442077 | 0.72 | CYP1A2 (0.41) | MEN1KMT2ACYP2C19CYP1A2ALDH1A1 | |
| SCHEMBL11985068 | 0.71 | ALDH1A1 (0.39) | MEN1KMT2APOLBMAPTALDH1A1 | |
| SCHEMBL19442050 | 0.70 | SETD7 (0.43) | MEN1KMT2APOLBCYP2C19MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9782382-B2 | TOFA analogs useful in treating dermatological disorders or conditions | DERMIRA (CANADA), INC. (US) | 2017-10-10 | — | — | US | disclosed |
| US-20160338988-A1 | TOFA ANALOGS USEFUL IN TREATING DERMATOLOGICAL DISORDERS OR CONDITIONS | DERMIRA (CANADA) INC (US) | 2016-11-24 | — | — | US | disclosed |
| US-9434718-B2 | TOFA analogs useful in treating dermatological disorders or conditions | DERMIRA (CANADA), INC. (US) | 2016-09-06 | — | — | US | disclosed |
| US-20150025069-A1 | TOFA ANALOGS USEFUL IN TREATING DERMATOLOGICAL DISORDERS OR CONDITIONS | DERMIRA CANADA INC (US) | 2015-01-22 | — | — | US | disclosed |
| US-8884034-B2 | TOFA analogs useful in treating dermatological disorders or conditions | DERMIRA (CANADA), INC. (US) | 2014-11-11 | — | — | US | disclosed |
| US-20120208807-A1 | TOFA ANALOGS USEFUL IN TREATING DERMATOLOGICAL DISORDERS OR CONDITIONS | Valocor Therapeutics, Inc. (CA) | 2012-08-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150025069-A1 | TOFA ANALOGS USEFUL IN TREATING DERMATOLOGICAL DISORDERS OR CONDITIONS | FAH, CUTA, ALOX5AP | MEN1 4056/4885KMT2A 2716/4885POLB 899/4885 |
| US-20160338988-A1 | TOFA ANALOGS USEFUL IN TREATING DERMATOLOGICAL DISORDERS OR CONDITIONS | FAH, CUTA, ALOX5AP | MEN1 4056/4885KMT2A 2716/4885POLB 899/4885 |
| US-20120208807-A1 | TOFA ANALOGS USEFUL IN TREATING DERMATOLOGICAL DISORDERS OR CONDITIONS | FAH, CUTA, ALOX5AP | MEN1 3929/4885KMT2A 3026/4885POLB 750/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.